ranibizumab

Trade name: lucentis

mAbapproved

Approved

Jun 30, 2006

Ranibizumab, sold under the brand name Lucentis among others, is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic that is approved to treat the "wet" type of age-related macular degeneration, diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion. — Wikipedia

Clinical trial activity

501 trials · 352 clinical orgs · 6 marketing orgs

Phase 1

101

Phase 2

273

Phase 3

147

Phase 4

104

Earliest trial started Jun 1, 2000 (NCT00570726)

Timeline

2000s

Jan 1, 2000
Earliest Phase 1 Sponsor(trial)
Jan 1, 2002
Genentech — Earliest Phase 3 Sponsor(trial)
Jan 1, 2004
Earliest Phase 2 Sponsor(trial)
Jun 30, 2006
Genentech — Earliest FDA Approval
Jun 30, 2006
Genentech — Marketing Organization
Jun 30, 2006
Genentech — NDA Organization

2020s

Sep 17, 2021
Samsung — Marketing Organization
Sep 17, 2021
Samsung — NDA Secondary Org
Oct 22, 2021
Roche — NDA Secondary Org
Aug 2, 2022
Sandoz — Marketing Organization
Aug 2, 2022
Coherus BioSciences — Marketing Organization
Aug 2, 2022
Coherus BioSciences — NDA Secondary Org
Dec 18, 2025
FORMYCON AG — Marketing Organization

Indications

Approved for

Studied for

Mechanism of action

Vascular endothelial growth factor receptor 2ANTAGONIST
KDR antagonist
- Vascular endothelial growth factor receptor 2 (KDR) ↗
Vascular endothelial growth factor AINHIBITOR
VEGFA inhibitor
- Vascular endothelial growth factor A (VEGFA) ↗
Erythropoietin receptorINHIBITOR
EPOR inhibitor
- Erythropoietin receptor (EPOR) ↗

Approval history

approvedJun 30, 2006

Chemistry & pharmacology

Chirality: Single Stereoisomer
Inorganic: No
Polymer: No
Delivery: Parenteral
Availability: Prescription Only
Multi-specific: No

Oral

Parenteral

Yes

Topical

Black box warning

Sources

Also known as

fab-12 variant y0317
lka651
lucentis
lucentis
lucentis
lucentis
pds 1.0
ranibizimumab
ranibizumab
ranibizumab
ranibizumab
ranibizumab
ranibizumab
ranibizumab
ranibizumab
ranibizumab
ranibizumab
ranibizumab
rfb002
rg-3645
rhufab
rhufab v2

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT07007065	Phase 3	Nov 5, 2025	AbbVie
NCT07249216	N/A	Jul 18, 2025	Singapore Eye Research Institute, Singapore National Eye Centre
NCT06847542	Phase 3	Jun 19, 2025	Genentech, Roche
NCT06957080	Phase 2/Phase 3 (Phase 3)	Apr 16, 2025	EyeBiotech Ltd.
NCT06571045	Phase 2/Phase 3 (Phase 3)	Aug 14, 2024	EyeBiotech Ltd.
NCT06708624	Phase 4	Jun 11, 2024	FORMYCON AG
NCT06305416	Phase 3	Mar 30, 2024	Incepta Vaccine Limited, Institute for Developing Science and Health Initiatives, Bangladesh
NCT06176352	Phase 3	Jan 30, 2024	Roche
NCT06190093	Phase 3	Jan 24, 2024	Outlook Pharmaceuticals
NCT06205979	Early Phase 1 (Phase 1)	Dec 12, 2023	Sohag University
NCT06176963	Phase 2	Nov 21, 2023	Samsung
NCT05562947	Phase 3	Feb 28, 2023	Roche
NCT06234514	Phase 4	Jan 1, 2023	Dongyang People's Hospital
NCT05861466	Phase 4	Jan 1, 2023	Ain Shams University
NCT05604989	Phase 3	Nov 1, 2022	Seoul National University
NCT05480293	Phase 3	Oct 15, 2022	Sinocelltech Ltd.
NCT05520177	Phase 3	Sep 30, 2022	Sunshine Lake Pharma Co., Ltd., Tianjin Medical University
NCT05386160	Phase 4	Jul 1, 2022	Jiao Tong University
NCT05439629	Phase 3	Jun 30, 2022	Anhui Medical University, Biothera, Capital Medical University, Central South University, China Medical University, Chongqing Medical University, Fudan University, Fujian Medical University, Guangzhou University, Guizhou Medical University, Hebei University, Inner Mongolia Medical University, Jiao Tong University, Jinlin University, Luoyang third people's Hospital, Nantong University, Ningbo Eye Hospital, Peking University, People's Hospital of Quzhou, Qingdao University, Shanghai Oriental Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai Xuhui District Central Hospital, Shanxi Medical University, Shenzhen University, Sun Yat-Sen University, Wenzhou Medical University, Zhejiang University, Zhengzhou University, Zunyi Medical College
NCT05461339	Phase 3	Jun 28, 2022	Chinese Academy of Medical Sciences, TOT Biopharm Co., Ltd., Zhaoke (Guangzhou) Pharmaceutical Limited

Showing 20 of 501 trials

Page 1 / 26

Organizations

Research & Development (352)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Genentech	For profit	109	17	5	2000
Novartis	For profit	102	65	5	2004
Allergan	For profit	18	12	3	2007
Roche	For profit	16	15	3	2015
National Eye Institute (NEI)	Government	15	7	3	2004
Johns Hopkins University	Academic/Hospital	10	10	3	2006
University of London	Academic/Hospital	9	8	4	2009
Greater Houston Retina Research	Academic/Hospital	8	4	4	2005
Jiao Tong University	Academic/Hospital	8	6	4	2013
Seoul National University	Academic/Hospital	8	6	4	2009
Sun Yat-Sen University	Academic/Hospital	8	7	4	2012
University of Sao Paulo	Academic/Hospital	8	8	3	2008
California Retina Consultants	Academic/Hospital	7	7	4	2006
Iveric Bio	For profit	7	6	3	2010
University of Vienna	Academic/Hospital	7	5	4	2007
Alcon	For profit	6	6	2	2010
Jaeb Center for Health Research	Academic/Hospital	6	6	2	2007
University of Bonn	Academic/Hospital	6	4	3	2007
University of California, San Francisco	Academic/Hospital	6	2	4	2006
Cairo University	Academic/Hospital	5	3	2	2015

352 organizations

Page 1 / 18

Marketing (10)

Organization	Org type	Relationship	Date
Coherus BioSciences	For profit	MKTG	Aug 2, 2022
Coherus BioSciences	For profit	NDA2	Aug 2, 2022
FORMYCON AG	For profit	MKTG	Dec 18, 2025
Genentech	For profit	MKTG	Jun 30, 2006
Genentech	For profit	SYN	Oct 22, 2021
Genentech	For profit	NDA	Jun 30, 2006
Roche	For profit	NDA2	Oct 22, 2021
Samsung	For profit	MKTG	Sep 17, 2021
Samsung	For profit	NDA2	Sep 17, 2021
Sandoz	For profit	MKTG	Aug 2, 2022